drugset / Trial / NCT04575610
IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess the efficacy of PF-06650833 in addition to standard-of-care compared to standard-of-care treatment alone in improving outcomes in patients with COVID-19.
Timeline
- Start
- 2020-11-27
- Primary completion
- 2021-10-06
- Completion
- 2021-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZIMLOVISERTIB | Small molecule | 200 mg | Oral |
| Subject | ZIMLOVISERTIB | Small molecule | 400 mg | Oral |